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Summary
Objectives
Bipolar depression is the most difficult-to-treat phase of bipolar 
disorder, in relation to its significant disruption of every-day life 
functioning and high suicidality risk. Despite the availability of 
several treatment options, the management of bipolar depres-
sion is still particularly challenging, with limited approved thera-
pies. Mood stabilizers and second-generation antipsychotics 
may not be as effective in ameliorating depressive compared to 
mood elevation symptoms, and entail substantial somatic toler-
ability limitations. In contrast, antidepressants are widely used 
off-label in bipolar depression (perhaps in part due to their bet-
ter somatic tolerability), but such use is controversial, as they 
may be associated with a higher risk of manic/hypomanic switch 
and rapid cycling. Among pharmacological augmentation strate-
gies, compounds with pro-dopaminergic activity such as stimu-
lants and stimulant-like agents (e.g., methylphenidate, modafinil 
and armodafinil) and dopamine agonists (e.g., pramipexole and 
ropinirole), have shown potential antidepressant effects, even 
though their use in clinical practice is still limited by the paucity 
of systematic evidence of efficacy and safety. The present review 
sought to summarize available evidence about such augmenta-
tive dopaminergic interventions for treatment-resistant bipolar 
depression, considering results of recent randomized controlled 
trials, as well as open studies, systematic reviews and guidelines 
indications.
Methods 
A systematic review of the literature was conducted. We first 
identified articles published in English and focused on the use 
of stimulants and dopamine agonists in bipolar disorder, using 
the keywords ‘stimulant’, ‘psychostimulant’, ‘amphetamine’, 
‘methylphenidate’, ‘modafinil’, ‘armodafinil’, ‘pramipexole’, 
‘ropinirole’, ‘dopamine agonists’, variably combined with ‘bipolar 
disorder’, ‘bipolar depression’, ‘major depression’ and ‘treatment-
resistant depression’. A second search was conducted about 
safety and tolerability, combining the keywords ‘stimulant’, 
‘psychostimulant’, ‘methylphenidate’, ‘modafinil’, ‘armodafinil’, 
‘pramipexole’, ‘ropinirole’, ‘dopamine agonists’ with ‘tolerability’, 
‘safety’, ‘side-effects’, ‘adverse events’, ‘discontinuation’, ‘drop out’, 
‘mania’, ‘suicide’, ‘cycle acceleration’. Additionally, reference lists 
of retrieved articles and proceeding of recent scientific meetings 
were manually searched for relevant publications. 
Results 
21 reports met the inclusion criteria and were herein reviewed 
in detail. 11 reports described of pramipexole in adult bipolar 
depression, including 2 double-blind RCTs targeting depressive 
symptoms, 1 double-blind RCT targeting cognitive dysfunction, 
and 8 open reports, and one report on the use of ropinirole in bi-
polar depression was identified. 10 reports focused on the use of 
adjunctive stimulant-like agents and stimulants, including 1 dou-
ble-blind armodafinil RCTs, and 1 double-blind modafinil RCT 
targeting depressive symptoms, 4 open uncontrolled modafinil 
studies, and 4 open uncontrolled methylphenidate studies. With 
respect to the use of stimulants in adult bipolar depression, al-
though systematic evidence is quite limited, available data seems 
to support their use in at least some bipolar depressed patients, 
especially when they show significant drowsiness or fatigue. In 
contrast, the use of the stimulant-like agents modafinil and ar-
modafinil seems to be more robust, supported by 2 RCTs as well 
as 4 open reports.
Conclusions
Taken as a whole, findings from reviewed studies seem to suggest 
that pro-dopaminergic compounds agonists, such as pramipex-
ole and stimulant-like agents, deserve consideration as potential 
adjunct therapeutic agents in adult bipolar depression, at least in 
specific subgroups of patients, although caution for supporting 
their use is still recommended. Future research and clinical trials 
on larger samples and greater follow-up periods are encouraged 
to extend available evidence and better clarify the potential role 
of these medications in bipolar depression. 
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Stimulants include several compounds with vari-
ous chemical structures and biological functions (i.e. 
amphetamines, methylphenidate, modafinil and ar-
modafinil), which are widely used to reduce fatigue and 
promote alertness and wakefulness. Although having 
a similar structure to amphetamine, methylphenidate 
is not a dopamine transport substrate, whereas it in-
creases the synaptic concentration of norepinephrine, 
serotonin and dopamine 20. Actually, it is indicated for 
the treatment of attention deficit hyperactivity disorder 
(ADHD) and narcolepsy 21 22, although it may be effec-
tive in the treatment of depression secondary to medical 
illness 23 24. Modafinil (2-(benzhydrylsulfinyl)acetamide) 
is a stimulant-like agent, previously thought to primarily 
enhance dopaminergic and noradrenergic neurotrans-
mission, secondarily enhance serotonergic, glutamater-
gic and histaminergic neurotransmission and influence 
orexinergic neurotransmission  25. Modafinil’s current 
putative chief mechanism is low-affinity dopamine 
transporter inhibition 26. Modafinil’s low affinity for the 
dopamine transporter compared to other agents could 
contribute to its lower abuse potential 27. Armodafinil 
is the R-enantiomer of racemic modafinil. Both have 
been approved by the United States Food and Drug Ad-
ministration (US FDA) to promote wakefulness, in case 
of excessive sleepiness associated with narcolepsy, ob-
structive sleep apnoea and shift-work sleep disorder 28. 
The European Medicines Agency (EMEA) limited the 
approved use of modafinil to narcolepsy 29 and has not 
approved armodafinil. Taken as a whole, stimulants 
and stimulant-like agents medications may be worth 
considering, since their use has been associated with 
significant improvement in wakefulness, attenuation of 
fatigue and appetite. In addition, the use of stimulants 
has been assessed in a variety of mood disorders (e.g. 
treatment-resistant depression, psychotic unipolar de-
pression, depression associated with medical disorders, 
geriatric depression, etc.). Moreover, these agents tend 
to be associated with somatic tolerability challenges 
comparable to antidepressants and less problematic 
than mood stabilizers or atypical antipsychotics. Results 
from clinical reports partially support their use in specif-
ic treatment-resistant depressive disorders, even though 
they highlight the possible risk of treatment-induced 
mood destabilization 30-32, particularly in bipolar depres-
sion 33. In fact, although they are likely to enhance cog-
nitive function, their use may be limited by the potential 
switch to manic and hypomanic phases.
In order to better understand the efficacy and safety of do-
pamine agonists and stimulants in treatment-resistant bi-
polar depression, we conducted the present study, aimed 
to review current evidence in the field.
Introduction
Bipolar disorder (BD) is a lifelong psychiatric illness that 
is responsible for severe impact on quality of life and 
causes substantial psychosocial and functional burden 1. 
Over the course of the illness, bipolar patients experience 
depression more often than mania 2 and the persistence 
of subsyndromal depressive symptoms, during euthymia, 
can increase the risk of relapse 3.
In spite of the advent of several alternative and adjunctive 
treatment options during last decades, the management 
of bipolar depression remains significantly challenging, 
with a limited number of established treatments. In fact, 
mood stabilizers and atypical antipsychotics may provide 
suboptimal relief of depressive symptoms while entailing 
substantial somatic tolerability challenges. Furthermore, 
even if antidepressants have superior somatic tolerability 
compared to mood stabilizers and atypical antipsychot-
ics, they are substantially limited in terms of their contro-
versial efficacy in bipolar compared to unipolar depres-
sion. In addition, antidepressants in bipolar patients have 
been associated with substantial psychiatric tolerability 
challenges, including risks of manic/hypomanic switch, 
rapid cycling and suicidality 4-7.
For these reasons, additional treatment strategies with ev-
idence-based efficacy and safety/tolerability support are 
under investigation in bipolar depression. In this perspec-
tive, according to recent international treatment guide-
lines for BD and bipolar depression, adjunctive treatment 
options targeting the dopaminergic system appear to be 
an attractive strategy in case of poor response. Among 
such strategies, dopamine agonists (i.e. pramipexole and 
ropinirole) and stimulants and stimulant-like agents (i.e. 
methylphenidate, modafinil and armodafinil) have gained 
growing interest for their potential antidepressant effects 
in bipolar depression.
Pramipexole and ropinirole are non-ergot dopamine ag-
onists. Pramipexole is a full agonist of the D3 subtype 
receptors, with very low affinity for D1 receptors and 
serotoninergic 5HT-2A and 2B receptors. Ropinirole acts 
as a D2, D3 and D4 dopamine receptor agonist, show-
ing highest affinity for D2 8 9. Pramipexole and ropinirole 
are approved for the treatment of Parkinson’s disease and 
restless leg syndrome. D3 receptors are diffusely distrib-
uted in the mesolimbic system  10 and appear to be in-
volved in the pathogenesis of motoric and anhedonic 
symptoms. In contrast to the ergot dopamine agonists, 
such as bromocriptine and pergolide, typically used for 
the treatment of Parkinson disease, pramipexole seems to 
fully activate dopamine receptors. After first evidence of 
its antidepressant effect in animal models 11-13, pramipex-
ole has shown similar activity in different trials involving 
patients with major depressive disorder 14, BD 15 16 and de-
pressed patients with Parkinson’s disease 17-19.
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Dopamine agonists
Published studies with adjunctive dopamine agonists (i.e. 
pramipexole and ropinirole) in bipolar depressed patients 
are summarized in Table I.
Pramipexole
In 1999, Goldberg and co-workers first described a 
positive effect for augmentation therapy of pramipex-
ole in two patients affected by treatment-resistant BD I 
depression  36. The first patient had a 23-year history of 
BD type I, with multiple hospitalizations and a relevant 
family history of bipolar illness. On the basis of clinical 
judgement, marked improvement in mood and overall 
functioning was reported within one week of treatment 
with pramipexole started at a dose of 0.25 mg/day and 
then increased to 0.75 mg/day. Euthymia persisted and 
no side effects were observed at 8-week follow up. The 
second patient, affected by BD type I with comorbid 
alcohol abuse (in remission) was on pharmacological 
treatment with olanzapine, topiramate and lamotrigine, 
which seemed to control mania and cycling, until a se-
vere depressive episode occurred. He was then started 
on 1 mg/day of pramipexole and, within 6 weeks, the 
depressive phase remitted. Improvement continued over 
the 6-month follow-up. The drug was well tolerated in 
this case, except for transient dose-related nausea.
In 2000, Sporn and colleagues evaluated the effective-
ness and safety of pramipexole as adjunctive medication 
in refractory unipolar and bipolar depression 37. Through 
retrospective chart review, they identified 20 patients with 
unipolar depression and 12 with bipolar depression who 
received pramipexole. In the bipolar depressed group, 
4 patients were rapid cyclers and the 78% of the entire 
sample was treated with antidepressants. The Clinical 
Global Impression-Improvement (CGI-I) 38 scale was used 
to assess effectiveness, being response defined as moder-
ate to marked improvement at the CGI-I. Pramipexole, 
administered at a mean dose of 0.7 mg/day for an average 
duration of 24.4 weeks, was found to be effective in 50% 
of patients with bipolar depression (6/12) and in 40% of 
patients with unipolar depression (8/20). In the bipolar 
group, there were no discontinuations of pramipexole for 
lack of efficacy, even though 3 subjects stopped because 
of side effects, whereas 8 unipolar patients dropped out 
for lack of efficacy and only 1 subject for side effects. 
These included: tremor, sedation, irritability, dry mouth, 
nausea, tics, urinary hesitancy, decreased appetite, vivid 
dreams, insomnia, transient word-finding difficulty and 
dizziness. On the basis of such findings, pramipexole 
seemed to be adequately tolerated and potentially useful 
in the adjunctive treatment of drug-resistant bipolar and 
unipolar depression.
A retrospective chart review of 18 bipolar II, treatment-
Methods
A systematic search of the literature, using MEDLINE and 
Cochrane Library, was conducted in two steps. First, we 
identified articles published in English and focused on 
the use of stimulants and dopamine agonists in BD, us-
ing the following keywords: “stimulant”, “psychostimu-
lant”, “amphetamine”, “methylphenidate”, “modafinil”, 
“armodafinil”, “pramipexole”, “ropinirole”, “dopamine 
agonists”, variably combined with “bipolar disorder”, 
“bipolar depression”, “major depression” and “treatment-
resistant depression”.
A second search was conducted in the area of safety 
and tolerability, combining the keywords “stimulant”, 
“psychostimulant”, “methylphenidate”, “modafinil”, 
“armodafinil”, “pramipexole”, “ropinirole”, “dopamine 
agonists” with the terms “tolerability”, “safety”, “side-
effects”, “adverse events”, “discontinuation”, “drop out”, 
“mania”, “suicide”, “cycle acceleration”. Additionally, 
reference lists of retrieved articles and proceeding of re-
cent scientific meetings were manually searched for rel-
evant publications.
Our main purpose was to specifically identify efficacy 
and safety studies on the adjunctive use of stimulants 
and dopamine-agonists in bipolar depression. Meta-anal-
yses, randomized clinical trials (RCTs), naturalistic and 
retrospective studies, case series, case reports and clini-
cal reviews were taken into consideration. On the other 
hand, single case-reports were not considered, in order 
to enhance the focus of the review. Further information 
regarding the use of these compounds in bipolar depres-
sion was obtained reviewing current international guide-
lines on BD treatment and conference proceedings 6 34 7 35.
Results
After excluding studies not specifically focusing on bipo-
lar depression, 21 reports met the inclusion criteria and 
were reviewed in detail. Eleven reports described prami-
pexole in adult bipolar depression, including 2 double-
blind RCTs targeting depressive symptoms, 1 double-
blind RCT targeting cognitive dysfunction and 8 open re-
ports. Only one report on the use of ropinirole in bipolar 
depression was identified. Ten reports focused on the use 
of adjunctive stimulant-like agents and stimulants, in-
cluding 1 double-blind armodafinil RCTs, 1 double-blind 
modafinil RCT targeting depressive symptoms, 4 open 
uncontrolled modafinil studies, and 4 open uncontrolled 
methylphenidate studies.
We first review studies on dopamine agonists (i.e. prami-
pexole, ropinirole) in bipolar depression, followed by re-
ports on stimulants and stimulant-like agents, listed by 
compound type (i.e. methylphenidate, modafinil and ar-
modafinil) and in chronological order.
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TAble I.
Published studies with adjunctive dopamine agonists (i.e. pramipexole, ropinirole) in bipolar depression.  
Studi pubblicati riguardo l’utilizzo di dopamino-agonisti (pramipexolo, ropinirolo) in associazione nella depressione bipolare.
Citation Study design Sample characteristics Study length Group dosage Outcome
Goldberg et al. 
(1999)
Open, case-series 2 bipolar I patients with treatment-resistant depression 8 weeks and 6 months, 
respectively
Adjunctive pramipexole 
(0.75 and 1 mg/day) 
Marked improvement in both cases, though standardized outcome measures were not used. Overall well 
tolerated, transient dose-related nausea in one patient
Sporn et al. 
(2000)
Open, retrospective chart 
review
32 subjects, including 12 treatment refractory, bipolar 
patients (subtype not specified); 33.3% had rapid cy-
cling features
Mean 24.4 weeks Adjunctive pramipexole 
(0.7 mg/day) 
Pramipexole effective in 50% of the sample, based on moderate to marked improvement on the CGI. 
No patient in the bipolar group stopped pramipexole due to lack of efficacy; 3 subjects interrupted 
pramipexole due to side-effects, mostly in the first 4 weeks of augmentation (tremor, sedation, irritabil-
ity, dry mouth, nausea, tics, urinary hesitancy, decreased appetite, vivid dreams, insomnia, transient 
word-finding difficulty, dizziness). One case of transient hypomania observed while no patient reported 
psychosis or sleep attacks
Perugi et al. 
(2001)
Open, retrospective chart 
review 
18 treatment resistant, bipolar II depressed subjects; 10 
treated with pramipexole and 8 with ropinirole 
Mean 17.6 weeks 
(range 4-34)
Adjunctive pramipexole 
(0.75 -1.5 mg/day), ad-
junctive ropinirole (1.5-
5 mg/day) 
Four patients (40%) were found to be pramipexole responders, based on CGI ratings of 1 or 2. Four pa-
tients (50%) were found to be ropinirole responders. Overall favourable tolerability. One patient had to 
stop pramipexole because of nausea, irritability and agitation
Lattanzi et al. 
(2002)
Open, prospective, naturalistic 
study 
37 subjects, including 21 bipolar subjects (17 included 
in the analyses: 11 BD II and 6 BD I)
16 weeks Adjunctive pramipexole 
(mean maximal dose 
0.95 mg/day) 
Significant decrease of MADRS and CGI-S scores observed; no difference in response rate between BD I 
(83.3%) and BD II (63.6%) subjects. The exact number of drop-outs in bipolar patients was not reported 
(within the original sample of 37 patients, 10 subjects discontinued pramipexole for adverse events). 
Most common side effects among completers were tremor and excitement/psychomotor retardation. 
Mixed tolerability along with a low rate of hypomanic switches




22 treatment-resistant, bipolar depressed patients (15 
BD I and 7 BD II), with baseline HAMD score > 18 
and YMRS score < 12, randomized to pramipexole 
(n = 12) or placebo (n = 10) 
6 weeks Adjunctive pramipex-
ole, (dose range 1-2.5 
mg/day) or placebo
67% of responders on pramipexole (≥ 50% reduction on the HAMD) vs. 20% of placebo patients. Mean 
HAMD change from baseline: 48% for pramipexole vs. 21.4% for placebo. 1 patient on pramipexole 
dropped out prematurely because of manic switch. Discontinuation rates for any cause were 17% for 
pramipexole (2/12) vs. 40% for placebo (4/10). Discontinuation rates due to lack of efficacy were 8% for 
pramipexole (1/12) vs. 30% for placebo (3/10). Nausea was reported more frequently in patients with 
pramipexole compared to placebo. Overall favourable tolerability 




21 bipolar II depressed patients, with drug-resistance 
features and baseline MADRS score > 20, randomized 
to pramipexole (n = 10) or placebo (n = 11)
6 weeks Adjunctive pramipex-
ole, (dose range 1-3 
mg/day) or placebo
Significant treatment effect reported. Treatment response (≥ 50% decrease on the MADRS) occurred in 
60% of patients on pramipexole vs. 9% of those on placebo. Discontinuation rates for any cause were 
10% for pramipexole (1/10) vs. 9.1% on placebo (1/11) and were due to lack of efficacy. One patient 
on pramipexole and 2 patients on placebo developed hypomanic symptoms (YMRS ≥ 12). Most of the 
reported side effects were similar for the treatment groups, except tremor, more frequently observed in 
pramipexole patients. Overall favourable tolerability
Cassano et al. 
(2004)
Open, long-term follow-up 
extension of previous study 
(Lattanzi et al., 2002)
11 bipolar, treatment-resistant, subjects (9 BD II and 2 
BD I)
6 to 12 months, me-
dian 28 weeks
Adjunctive pramipexole 
(dose range 0.75-1.5 
mg/day)
Efficacy and safety data for bipolar sub-group were not separately reported. In the overall sample, 60.9% 
were remitters. 2 bipolar subjects developed hypomania and psychotic mania. In the overall sample, 5 
adverse events reported (21.7%): psychomotor agitation, ataxia, impulse dyscontrol, vomiting and hypo-
mania. Overall mixed safety/tolerability and presumably positive effectiveness for pramipexole in the mid/
long term follow-up
Gupta et al. 
(2006)
Retrospective case series 2 bipolar I, treatment-resistant depressed, subjects 8 to 18 weeks Adjunctive pramipexole 
(dose range 0.75-1.5 mg/
day)
Significant improvement in HAMD total scores, from the second week of augmentation onward. No 
significant side effects noted
Akdeniz et al. 
(2009)
Retrospective case series 2 bipolar, treatment-depressed, subjects (1 BD I) 6 to 8 months Adjunctive pramipexole 
(dose range 0.5-0.75 
mg/day)
Assessment, based exclusively on clinical impressions, showed a decrease in severity and duration of de-
pressive episodes in the mid-term observation. Sleep and gastrointestinal side-effects were reported exclu-
sively in the short-term, whereas no serious adverse event was observed during the maintenance treatment
El Mallakh et 
al. (2010)
Retrospective chart review 16 bipolar patients (13 BD I) Average 6.7 ± 9 
months
Adjunctive prami-
pexole (average dose 
1.03 ± 0.65 mg/day)
62.5% of the sample benefited from treatment and 50% of patients remained on pramipexole for > 3 
months. The severity of depressive symptoms dropped significantly within 4 weeks. CGI and GAF scores 
showed a consistent improvement. Half of the patients stopped pramipexole an average of 2 months after 
starting it. Common adverse events were: insomnia (41.2%), irritability (31.5%), nausea (25%), anxiety 
(25%) and sleepiness, lethargy and dizziness (12.5% of the sample each). Six patients (37.5%) stopped 
pramipexole due to adverse effects. Manic symptoms did not worsen at any time during study. Overall 
favourable effectiveness data, mixed results in terms of safety and tolerability




50 bipolar patients (subtype not specified) 8 weeks Adjunctive pramipexole 
(target dose 1.5 mg/day)
A significant overall effect for treatment on neurocognitive functioning was found in the euthymic subgroup 
of patients. Higher levels of baseline cognitive impairment were associated with greater cognitive improve-
ment after pramipexole treatment. Pramipexole did not cause any discontinuation due to adverse event
BDI: Bipolar disorder type I; SD: Standard deviation; HAMD: Hamilton Depression Rating Scale; ADHD: Attention Deficit Hyperactivity Disorder; 
CGI-BP: Clinical Global Impression Scale for Bipolar Disorder; BZs: Benzodiazepines.
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months. The severity of depressive symptoms dropped significantly within 4 weeks. CGI and GAF scores 
showed a consistent improvement. Half of the patients stopped pramipexole an average of 2 months after 
starting it. Common adverse events were: insomnia (41.2%), irritability (31.5%), nausea (25%), anxiety 
(25%) and sleepiness, lethargy and dizziness (12.5% of the sample each). Six patients (37.5%) stopped 
pramipexole due to adverse effects. Manic symptoms did not worsen at any time during study. Overall 
favourable effectiveness data, mixed results in terms of safety and tolerability




50 bipolar patients (subtype not specified) 8 weeks Adjunctive pramipexole 
(target dose 1.5 mg/day)
A significant overall effect for treatment on neurocognitive functioning was found in the euthymic subgroup 
of patients. Higher levels of baseline cognitive impairment were associated with greater cognitive improve-
ment after pramipexole treatment. Pramipexole did not cause any discontinuation due to adverse event
BDI: Bipolar disorder type I; SD: Standard deviation; HAMD: Hamilton Depression Rating Scale; ADHD: Attention Deficit Hyperactivity Disorder; 
CGI-BP: Clinical Global Impression Scale for Bipolar Disorder; BZs: Benzodiazepines.
332
B. Dell’Osso et al.
did not significantly differ between the two groups at 
endpoint. Nausea was more common in subjects on 
pramipexole compared to placebo.
In the same year, another randomized, double blind, pla-
cebo-controlled trial, assessing the antidepressant effect 
of augmentative pramipexole was conducted by Zarate 
and colleagues  16. In this study, 21 patients affected by 
BD II were enrolled. Patients were experiencing a major 
depressive episode despite pharmacological treatment 
with lithium or valproate, and were randomly assigned 
to adjunctive placebo (n = 11) or pramipexole (n = 10) 
for 6 weeks. Pramipexole was initiated at 0.375 mg/
day and gradually increased to a range of 1-3 mg/day. 
All patients, except one taking placebo and one taking 
pramipexole, completed the study. Treatment response 
(> 50% decrease in MADRS score) was reported in 60% 
of subjects taking pramipexole vs. 9% of subjects taking 
placebo. Hypomania was experienced by 2 patients tak-
ing placebo and one patient taking pramipexole, and the 
most common side effect in patients treated with prami-
pexole was tremor.
In 2004, Cassano and colleagues extended acute evalu-
ation of pramipexole effects to the mid/long term, after 
recruiting 23 adults with treatment-resistant major de-
pressive episodes, 11 of which had bipolar depression 44. 
Patients were followed up for additional 6 to 12 months, 
after a 16-week pramipexole add-on trial, with doses 
ranging from 0.75 to 1.5 mg/day. Baseline assessment 
of depression with MADRS and CGI-S was followed by 
a 16-, 32-, and 48-week assessment. At the endpoint, 
pramipexole was found to be efficacious: 14 of 23 pa-
tients (60.9%) experienced remission, defined as at least 
8 weeks of no depressive symptoms or just residual symp-
toms, with a mean time of 10 weeks. The authors report-
ed 5 adverse events (21.7%) in the entire sample resulting 
in pramipexole discontinuation (psychomotor agitation, 
ataxia, impulse dyscontrol, vomiting and hypomania).
In 2006, Gupta and co-workers reported a retrospec-
tive case series of 3 patients treated with augmentative 
pramipexole 45. Two subjects had BD I, and were taking 
antidepressants and atypical antipsychotics. Depressive 
symptoms were assessed with the HAMD, at baseline, 
and at 2 and 8 weeks after the beginning of the treatment 
with pramipexole, which was started and maintained at 
doses of 0.75-1.5 mg/day. The improvement of depressive 
symptoms was documented by HAMD score reductions 
from 24 to 7 and from 21 to 6, for the 2 patients, respec-
tively, at the follow-up visit, 2 weeks later. As no signifi-
cant side effects were noted, the authors gave support to 
tolerability and effectiveness of pramipexole in refractory 
depression.
In 2009, Akdeniz and colleagues reported on two bipolar 
patients with recurrent long-term and severe depression 
treated with augmentative pramipexole 46. Although based 
resistant depressed patients was conduced by Perugi and 
colleagues in 2001  39. These subjects were treated with 
augmentative dopamine agonists, i.e. pramipexole (10 
subjects) and ropinirole (8 subjects), added to on-going 
treatment with antidepressants and mood stabilizers. Pa-
tients treated with pramipexole received a mean dose of 
0.75-1.5 mg/day for a mean duration of 17.6 weeks. Four 
patients (40%) were found to be pramipexole responders 
(Clinical Global Impression Scale CGI-S38 ratings of 1 or 
2), and two other patients showed mild response, con-
sidered as a CGI-S score of 3. Pramipexole did not cause 
major side effects, being well tolerated, with no negative 
interactions with concomitant psychotropic medications. 
One patient had to interrupt it due to nausea, increased 
agitation and irritability.
In 2002, Lattanzi and co-workers conducted a 16-week 
naturalistic study, aimed to assess the efficacy and tolera-
bility of adjunctive pramipexole in subjects with drug-re-
sistant depression 40. Thirty-seven patients were enrolled: 
16 with unipolar depression and 21 with bipolar depres-
sion; 31 subjects were included in the analyses and 19 
patients completed the 16-week follow-up. Pramipexole 
was added to antidepressant treatment (SSRIs or TCAs) 
and was initiated at a dose of 0.375 mg/day, increased to 
a maximum of 1 mg/day in the third week. Patients were 
defined responders if they had a  >  50%-reduction on 
Montgomery-Åsberg Depression Rating Scale (MADRS) 41 
total score or a CGI-S score of 1 or 2. At the endpoint, 
67.7% were considered MADRS responders and 74.2% 
met response criteria on the basis of CGI-S. BD I patients 
did not significantly differ from BD II ones in terms of 
response rate. The authors reported relatively adequate 
tolerability: most commonly observed side effects includ-
ed excitement/psychomotor retardation and tremor. Two 
cases of hypomanic switch were reported.
In 2004, Goldberg and colleagues conducted a rand-
omized, double-blind, placebo controlled trial, recruit-
ing 22 patients: 15 affected by BD I and 7 by BD II, with 
a baseline Hamilton Depression Rating Scale (HAMD) 42 
score  >  18 and Young Mania Rating Scale (YMRS)  43 
score < 12 15. All patients had an inadequate response to 
at least two trials of antidepressants, used in association 
with mood stabilizers. Subjects were randomly assigned 
to receive, in addition to mood stabilizers such as lithi-
um or anticonvulsants, placebo (n = 10) or pramipexole 
(n = 12), administered in a range of 1-2.5 mg/day for 6 
weeks. At the end of the study, pramipexole was found 
to be superior to placebo in terms of efficacy: 67% of 
patients on pramipexole were responders (HAMD score 
reduction > 50%), whereas only 20% of subjects on pla-
cebo were considered responders. Of note, the discon-
tinuation rate for any cause was 40% for placebo vs. 17% 
for pramipexole. Although one patient taking pramipex-
ole dropped out for a manic switch, mean YMRS scores 
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on 18 bipolar depressed treatment-resistant patients on 
therapy with dopamine agonists to assess their effective-
ness and safety as add-on medications in refractory bipo-
lar depression 39. Patients were defined responders on the 
base of CGI-S, with ratings of 1 or 2. In particular, 8 sub-
jects were treated with ropinirole, receiving a mean dose 
of 2.97 mg/day (range: 1.5-5 mg/day); 4 patients (50%) 
showed response on the basis of CGI-S. Ropinirole was 
well tolerated and did not show any negative interaction 
with concomitant psychiatric medications.
Stimulant-like agents and stimulants
Clinical reports on the use of adjunctive methylpheni-
date, modafinil and armodafinil in bipolar depression are 
reported in Table II.
Methylphenidate
In 2000, El-Mallakh conducted an open, 12-week, trial 
with 14 mildly-depressed bipolar patients (including 10 
with BD type I) with HAMD score ≥ 15, and treated with 
10-20 mg/day of methylphenidate in addition to a sta-
ble mood stabilizing regimen 50. Three patients withdrew 
from the trial, because of increased agitation, anxiety and 
hypomania. The results showed a relevant improvement 
in both depressive and global psychiatric symptoms, as 
confirmed by a moderate decrease in mean HAMD scores 
from 16.9 ± 1.79 at baseline, to 9.4 ± 9.7 at endpoint, as 
well as a quite significant decrease in Psychiatric Symp-
tom Assessment Scale (PSAS) 51 scores from 17.9 ± 5.63 to 
4.8 ± 7.47. In conclusion, authors reported that the use of 
methylphenidate was effective and relatively safe for the 
treatment of bipolar depressed subjects.
In 2004, Carlson and colleagues retrospectively reported 
on 8 patients with BD (5 with BD type I and 3 with BD 
type II) who received adjunctive stimulants (either meth-
ylphenidate or amphetamine) for a mean duration of 18 
months to improve residual depression and medication-
induced sedation 52. A moderate clinical relief from target 
symptoms was associated with consistent improvement 
of overall bipolar illness, as assessed by a mean improve-
ment in CGI-S score of 2.9 points from baseline to the 
time of last visit. The adequate tolerability and the ab-
sence of induced hypomania, mania, increased cycling 
or abuse seemed to support the use of these compounds 
as reasonable therapeutic option in individuals who do 
not properly respond to standard treatment.
Two years later, Lydon and El-Mallakh conducted a ret-
rospective chart review of 16 bipolar patients (9 with BD 
I, 7 with BD II, 1 with cyclothymia and 1 bipolar not 
otherwise specified) receiving methylphenidate for 14 
months, on average, to assess its long-term tolerability, 
safety and efficacy 53. The mean dose of methylphenidate 
only on clinical impressions, patients benefited from low 
dose of augmentative pramipexole (0.5-0.75 mg/day): the 
duration and the severity of the depressive episode was 
markedly decreased in the mid-term observation after 6 
to 8 months of follow-up. No serious adverse events were 
observed during follow-up, with the exception of sleep 
and gastrointestinal side-effects, both reported only dur-
ing short-term treatment.
In 2010, a naturalistic retrospective chart review of 16 
bipolar depressed patients treated with augmentative 
pramipexole was conducted by El Mallakh and co-work-
ers 47. In order to assess the safety and efficacy of prami-
pexole, it was administered at an average dose of 1 mg/
day for a mean duration of 6.7 months. Even though half 
of patients did not remain on pramipexole for more than 
3 months, 10 subjects (62.5%) benefited from treatment: 
depressive symptoms improved within 4 weeks and their 
severity remained low for up to 9 months. CGI-S and Glo-
bal Assessment of Functioning (GAF) 48 scores both im-
proved with pramipexole. However, adverse events were 
quite common: half of patients stopped pramipexole after 
an average of 2 months from the beginning of treatment 
because of insomnia (41.2%), irritability (31.5%), nausea 
(25%), anxiety (25%) and sleepiness, lethargy and diz-
ziness (12.5% each). No changes in mania ratings were 
reported at 36 months.
Recently, Burdick and colleagues aimed to assess the ef-
fects of adjunctive pramipexole on cognition by recruit-
ing 50 stable outpatients in an 8-week, double-blind, ran-
domized, placebo-controlled trial, including neurocogni-
tive assessment at baseline and 8 weeks later  49. Forty-
five patients completed the study: 24 received placebo, 
whereas 21 subjects were treated with pramipexole, 
starting from 0.25 mg/day to a target dose of 1.5 mg/day. 
At study endpoint, no relevant effect of treatment group 
on measures of depression and mania was reported, as 
well as no switching to mania/psychosis or discontinu-
ation due to adverse events. Among subjects on prami-
pexole, the only side effect was restlessness. Although 
primary cognitive analyses did not highlight significant 
cognitive benefit from pramipexole, secondary data iden-
tified a subgroup of patients who might rapidly experi-
ence advantages from cognitive enhancement strategies. 
In particular, the euthymic subgroup of patients appeared 
to show a significant overall effect of treatment on neu-
rocognitive functioning. Furthermore, higher levels of 
cognitive deficits were related to a more pronounced 
improvement in cognitive performance after pramipexole 
treatment.
Ropinirole
In one of the aforementioned studies, Perugi and co-
workers, in 2001, conducted a retrospective chart review 
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TAble II.
Published studies with adjunctive methylphenidate, modafinil and armodafinil in bipolar depression.  
Studi pubblicati riguardo l’utilizzo di metilfenidato, modafinil e armodafinil in associazione nella depressione bipolare.
Citation Design Sample characteristic Study lengths Group dosage Outcomes Conclusions
El-Mallakh 
(2000)
Open, prospective study 14 bipolar (10 BDI, 3 with prior alcohol abuse); de-
pressed patients on mood stabilizing treatment
12 weeks Adjunctive methylpheni-
date (10-20 mg/day)
44% decrease in mean HAMD score. 3 patients discontinued 
due to anxiety, agitation, hypomania
Adjunctive methylphenidate to mood 
stabilizers effective and relatively safe
Menza et al. 
(2000)
Open, retrospective case series 
of depressed (including bipo-
lar) patients
Subgroup of 3 bipolars with depression and residual 
tiredness/fatigue, despite antidepressants
10-12 weeks Adjunctive modafinil 
100-200 mg/day
All had full/partial remission, mostly in 1-2 weeks. Residual 
tiredness/fatigue were particularly responsive. Side-effects 
minimal, did not cause any discontinuation
Adjunctive modafinil to antidepres-
sants relieved depression, tiredness 
and fatigue, and was relatively safe
Fernandes and 
Petty (2003)
Open, prospective case series 2 bipolars (1 BDI, 1 with prior comorbid substance 
abuse, 1 with current comorbid medical conditions) 
with excessive daytime sleepiness, taking mood stabi-
lizers
8 weeks Adjunctive modafinil 
100-400 mg/day
Significant rapid improvement in drowsiness and functioning. 
No hypomanic/manic switch or side-effects
Adjunctive modafinil to mood stabiliz-
ers for residual drowsiness was effec-
tive and well-tolerated
Carlson et al. 
(2004)
Open, retrospective case series 8 depressed bipolars (5 BDI, comorbidities other than 
ADHD allowed); despite variable concomitant medi-
cations
Mean 18 months 
(range 11-24)
Adjunctive methylpheni-
date (10-20 mg/day) or 
amphetamines (unspeci-
fied dose)
Robust mean CGI-BP improvement 2.9) with prolonged treat-
ment. No switch reported
Adjunctive methylphenidate/amphet-
amines to various medications were 
effective and relatively safe
Nasr (2004) Open, retrospective chart re-
view of mood (including bipo-
lars) patients
Unspecified subgroup of depressed bipolars taking an-
tidepressants
Un-specified Adjunctive modafinil 
(un-specified doses)
Positive outcome, particularly in those with problematic 
sleepiness or fatigue
Adjunctive modafinil to antidepres-
sants yielded benefit
Lydon and El 
Mallak (2006) 
Open, retrospective chart re-
view
16 bipolar (9 BDI, 5 also with ADHD); depressed sub-
jects despite mood-stabilizing therapy
Mean 14 months 
(range 1-60)
Adjunctive methylpheni-
date mean dose 16.3 mg/
day (range 5.40 mg/day) 
Most had attenuation of depression and inattention. (Gener-
ally mild) adverse events in 62% – irritability in 19%, agi-
tation in 13% – no mania/hypomania, cycling exacerbation, 
nor substance abuse induction
Adjunctive methylphenidate to mood 
stabilizers and BZs was effective in 
most patients and relatively safe
Nasr et al. 
(2006)
Open, retrospective chart re-
view of mood patients (in-
cluding bipolars) receiving 
modafinil at some point
Subgroup of 64 depressed bipolars (31 BDI) mostly tak-
ing other medication(s)
< 2 months to 2 years Adjunctive (most often) 
modafinil mean 230-287 
mg/day
Modafinil maintenance: < 2 months in 25 bipolars (13 BDI); 2 
months in 39 bipolars (18 BDI); 1 yr in 27 bipolars (11 BDI); 2 
years in 16 bipolars (BDI = 7). No manic/hypomanic switch, 
abuse. Modafinil dosage relatively stable
Adjunctive modafinil to other medica-
tions did not induce manic/hypomanic 
switches or tolerance/abuse indepen-
dent of history of chemical abuse/de-
pendence
Frye et al. 
(2007)
Randomized, double blind, 
placebo controlled, multisite 
acute study
85 bipolars (64 BDI) with major depressive episode 
(IDS > 16) despite treatment with mood stabilizer or 
antidepressant
6 weeks Adjunctive modafinil 
200 mg/day (n = 41) vs. 
placebo (n = 44)
Adjunctive modafinil compared to placebo yielded greater 
improvement on mean IDS, IDS 4-item fatigue and energy 
subset and CGI depression severity, as well as higher IDS re-
sponse/remission rates, and similar incidence of treatment-
emergent hypomania/mania, and blood pressure, heart rate, 
and weight effects. Headache was most common modafinil 
side-effect
Adjunctive modafinil to mood stabiliz-
er or antidepressant improved depres-
sive symptoms with good tolerability
Calabrese et 
al. (2010)
Randomized, double blind pla-
cebo controlled multisite acute 
study
258 bipolar I with major depressive episode 
(HAMD ≥ 20) despite treatment with lithium, olanzap-
ine or valproic acid 
8 weeks Adjunctive armodafinil 
150 mg/day (n = 128) vs. 
Placebo (n = 129)
Adjunctive armodafinil compared to placebo yielded greater 
improvement in depressive symptoms on mean IDS (but not 
on secondary outcomes), and similar incidence of medical 
and psychiatric adverse events (but more insomnia, restless-
ness, anxiety and hypomania)
Adjunctive armodafinil to lithium, 
olanzapine, or valproic acid improved 
depressive symptoms, for some out-




Open, prospective case series 
of 50 patients with depressive 
disorders (including bipolars)
27 bipolars (5 BDI) with history of persistent and/or 
recurrent treatment-resistant depression; depressed de-
spite (in most cases) psychotropic medications
Mean 57 weeks 
(range 6-250) (among 
patients continuing 




mg/day, modal 20 mg/
day) or dextroamphet-
amine (few cases) 
34% distinct improvement in depression, 30% some im-
provement in depression, 36% no improvement in depression 
and/or side effects. Rapid positive responses, only rare loss of 
efficacy. Significant side effects in 18% – mostly minor, but 1 
mania; switching rare and limited to bipolars
Adjunctive methylphenidate to other 
psychotropics was variably effective 
and relatively safe
BDI: Bipolar disorder type I; SD: Standard deviation; HAMD: Hamilton Depression Rating Scale; ADHD: Attention Deficit Hyperactivity Disorder; 
CGI-BP: Clinical Global Impression Scale for Bipolar Disorder; BZs: Benzodiazepines.
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Open, retrospective chart re-
view
16 bipolar (9 BDI, 5 also with ADHD); depressed sub-
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side-effect
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8 weeks Adjunctive armodafinil 
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Adjunctive armodafinil compared to placebo yielded greater 
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tients (including 13 BP I), for ≥ 2 months in 39 (including 
18 BP I), for ≥ 1 year in 27 (including 11 BP I) and for ≥ 2 
years in 16 (including 7 BP I). Reasons leading to discon-
tinuation of modafinil were lack of efficacy, cost or adverse 
events, which were mostly sleep-related. No manic/hypo-
manic switch was observed, reinforcing the overall safety 
and tolerability of the compound in long-term treatment.
In 2007, Frye and colleagues conducted an acute phase, 
6-week, randomized, double-blind placebo-controlled 
study of 85 bipolar depressed patients (including 64 BD I), 
inadequately responsive to mood stabilizers with or with-
out antidepressant treatment and randomly assigned to 
receive adjunctive modafinil or placebo 60. Improvement 
in Inventory Depressive Symptoms-Clinician Rated score 
(IDS)  61 was significantly greater with modafinil (mean 
dose of 174.2 mg/day) compared to placebo. Scores on 
the IDS, the four-item fatigue-and-energy subset of the 
IDS, and the CGI-BP depression severity item signifi-
cantly improved with modafinil compared to placebo. 
Headache was the most common side effect apparently 
induced by modafinil, whereas no significant differences 
in treatment-induced mania, blood pressure, heart rate 
or weight gain were observed between the two groups. 
Taken together, these data support the role of adjunctive 
modafinil in improving symptoms of bipolar depression, 
without inducing mood destabilization.
In 2010, Calabrese and co-workers evaluated safety and 
efficacy of armodafinil as adjunctive compound in bipo-
lar depression 62. In an 8-week, multicenter, randomized, 
double-blind, placebo-controlled study, bipolar I de-
pressed patients on treatment with lithium, olanzapine 
or valproate were randomly assigned to adjunctive ar-
modafinil (mean dose 150 mg/day) or placebo. Greater 
improvement was seen in patients receiving armodafinil 
as confirmed by a significant decrease in the Inventory of 
Depressive Symptomatology, Clinician-Rated (IDS-C30) 
used as a primary outcome measure. No differences were 
reported in secondary outcomes, including MADRS. 
Among induced side effects, headache, diarrhoea and in-
somnia were the most frequently reported. No increased 
incidence and/or severity of suicidality, depression, or 
mania or changes in metabolic profile occurred.
Discussion
Herein, the available evidence on the use of augmenta-
tive pro-dopaminergic agents, including stimulants and 
dopamine agonists, in the treatment of bipolar depres-
sion has been overviewed. Examining results on the use 
of pramipexole from either double-blind or open stud-
ies, the short-term efficacy and tolerability/safety of the 
compound, when used in augmentation, is adequately 
supported by controlled data. On the other hand, even 
though some open observations seem to support the mid/
was 16.3 mg/d ± 8.7 mg/day, ranging from 5 to 40 mg/
day, and it appeared to be generally well tolerated, lead-
ing to a significant symptomatic relief (GAF score). Sev-
eral mild to moderate side effects were reported, mainly 
represented by increased irritability and agitation, which 
were responsible for discontinuation of methylphenidate 
in two patients.
In 2010, Parker and Brotchie reported a case series of 
50 subjects with treatment-resistant depression, includ-
ing 27 bipolar patients, treated with methylphenidate or 
dexamphetamine, either as monotherapy or augmenta-
tive drugs 54. After a mean duration of 57 weeks of follow-
up, with a modal dose of 20 mg/day, 34% of patients 
reported a significant improvement in target symptoms, 
30% some level of amelioration, while 36% revealed no 
substantial differences. Switching was rare and limited to 
bipolars, and most adverse effects, reported by 18% of 
the sample, were mild. Furthermore, positive response 
seemed to occur rapidly and loss of efficacy was unusual.
Modafinil and armodafinil
In 2000, Menza and colleagues reported a retrospective 
case series of 7 depressed patients (including 3 subjects 
with bipolar depression) treated with augmentative mo-
dafinil to improve partial or nonresponse to antidepres-
sants 55. The entire sample fully or partially remitted after 
1-2 weeks of treatment with 100-200 mg/day of modafin-
il. Residual tiredness or fatigue, observed in all individu-
als prior to starting modafinil, were particularly respon-
sive to augmentation. Side effects were limited and did 
not lead to treatment discontinuation in any patient.
In 2003, Fernandes and Petty described two bipolar pa-
tients with recent depressive episodes in remission with 
prominent residual hypersomnia 56. In spite of adequate 
pharmacological treatment with mood stabilizers and 
antidepressants, patients continued to experience exces-
sive daytime sleepiness that significantly improved with 
the addition of modafinil at a dose of 100-400 mg/day for 
8 weeks, as confirmed by Epworth Sleepiness Scale score 
(ESS) 57. No side effects or mood changes were reported.
In 2004, Nasr conducted a retrospective chart review of 
78 depressed outpatients, including bipolar subjects, in 
a general psychiatric practice, receiving adjunctive mo-
dafinil to antidepressant therapy 58. Significant improve-
ment in wakefulness, fatigue and everyday functioning 
was observed, along with overall favourable tolerability.
Two years later, Nasr and co-workers performed a retro-
spective chart review of 191 patients with mood disorders 
(including 64 depressed bipolar subjects, 31 BP I and 33 
BP II), who were given modafinil at some point during their 
treatment to assess switching, dose stability and abuse li-
ability 59. Modafinil was generally administered at a dose 
ranging from 250 to 290 mg/day, for < 2 months in 25 pa-
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long term effectiveness of the compound, other reports 
(i.e. Lattanzi 40, Cassano 44 and El-Mallakh 47) have reaised 
safety and tolerability concerns.
The open case series reported by Perugi et al. in 2001 
seems, in turn, to provide evidence for the efficacy of 
augmentative ropinirole in treatment-resistant bipolar II 
depression. Nevertheless, evidence on the use of rop-
inirole as add-on, in the treatment of treatment-resistant 
bipolar depression, relies upon this single report. Accord-
ingly, at present, the compound cannot be recommended 
as augmentative intervention, due to the limited number 
of treated cases.
Considering the use of stimulants in adult bipolar depres-
sion, although the systematic evidence is quite limited 
(no RCTs and 4 open reports), the available data seems to 
advocate their use in at least some bipolar depressed pa-
tients, especially when significant drowsiness or fatigue is 
present. In contrast, the evidence to support the use of the 
stimulant-like agents modafinil and armodafinil is more 
robust, supported by 2RCTs as well as 4 open reports.
Taking into account the quality and quantity of published 
studies to date, adjunctive dopamine agonists and stimu-
lants cannot be, at present, included among well-estab-
lished, evidence-based strategies for treatment of bipolar 
depressed patients who fail to respond to first-line inter-
ventions. Such perspective is consistent with recommen-
dations of recent international guidelines for treatment of 
BD 6 34 7 35.
However, the emerging evidence regarding the stimulant-
like agent armodafinil indicates that in the not too distant 
future there may be sufficient support to recommend its 
use in bipolar depressed patients who fail to respond to 
first-line interventions.
Regarding the efficacy of pramipexole, Aiken and col-
leagues suggested that augmentative pramipexoleis a 
valid therapeutic option for treatment-resistant bipolar 
depression, and reported a large effect size (0.77-1.1) 63 
on the basis of two very small previous RCTs 15 16. Sub-
sequent reports appear to be consistent with this per-
spective, allowing researchers to speculate about the 
mechanism of action of these compounds in bipolar 
depression. Dopaminergic enhancement, for instance, 
may promote the action of antidepressant medications, 
particularly in patients complaining of a lack of energy 
and motivation 64 65. Furthermore, it has been suggested 
that a resensitization and potentiation of mesolimbic D2/
D3 receptors, indicated as the final common pathway of 
the long-term use of antidepressants 66 67, may represent 
one of the key antidepressant effects of pramipexole and 
ropinirole. In addition, the neurotrophic, neuroprotective 
and antioxidant activity shown by pramipexole in cell 
cultures 68 8 69 70 may, at least partially, account for its anti-
depressant properties, even though evidence is mainly 
based on preclinical level investigation 71.
Focusing on the efficacy of stimulants, it is worth noth-
ing that the recruitment of patients experiencing symp-
toms effectively treated by stimulants, such as sleepiness 
or fatigue 32, may be partially responsible for the positive 
results. Although this may help in identifying a subgroup 
of subjects who may benefit from a more personalized 
treatment 72, on the other hand, it could limit the general-
izability of findings. In addition to sample heterogeneity, 
another issue that should be considered is the possible 
influence of concurrent medications (such as mood sta-
bilizers) on clinical results, potentially leading to discrep-
ancy observed in some studies.
In terms of safety/tolerability, combined data from 8 stud-
ies, up to 2004, had previously shown a discontinuation 
rate of 9% among patients with mood disorders taking 
pramipexole  63. Nonetheless, this encouraging finding of 
adequate short-term tolerability has not been confirmed in 
the mid- to long-term by subsequent open reports, docu-
menting higher drop-out rates for a total of 33 patients. 
In the short-term, favourable somatic tolerability and low 
risk of switch or mood destabilization have been generally 
documented with both adjunctive pramipexole and stimu-
lants. This may be related to the concomitant presence of 
antimanic agents in the patients’ pharmacological treat-
ment and, compared to pramipexole, to the administration 
of a lower dosage for a shorter duration compared to pa-
tients with Parkinson’s disease. In fact, the potential switch 
to mania or psychosis induced by dopaminergic com-
pounds such as pramipexole, along with other psychiatric 
and somatic adverse effects, may occur less frequently in 
psychiatric patients than those with Parkinson’s disease55, 
being likely related to the absence of ongoing antimanic 
therapy and the degeneration of extrastriatal dopaminergic 
pathways 73 63. However, it is worth noting that investiga-
tions on dopamine agonists in the long-term treatment of 
bipolar patients are scanty and further investigations may 
reveal higher rates of switching into mania 16.
Likewise, specific concerns about the possibility of mania 
induced by stimulants 74-76 may have been related to the 
absence of concomitant antimanic therapy 52 and further 
risks, including earlier onset and more severe course, 
have been reported for BD adolescents, with previous ex-
posure to stimulants 77 78. On the other hand, low abuse 
potential has been reported for the stimulant-like agents 
modafinil or armodafinil compared to stimulants 79. The 
reviewed studies did not highlight the risk for potential 
stimulant misuse/abuse, and documented low rates of 
misuse for methylphenidate over several months or even 
years of observation 52-54. This may be due to the exclusion 
of subjects at high risk of stimulant abuse.
With regard to induced side effects, gradual pramipexole 
titration has been recommended to limit the occurrence 
of orthostatic hypotension, tremors, somnolence, insom-
nia, dizziness and nausea. No significant drug-interac-
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tions 31, weight gain potential or sexual side effects have 
been described in clinical studies. Similarly, controlled 
trials for modafinil and armodafinil have not documented 
any significant difference versus placebo with regards to 
blood pressure, heart rate or weight 60, laboratory values, 
ECG parameters and physical examination findings  62. 
The safety of stimulants, also sustained by their low drug-
interaction potential and the limited absolute medical 
contraindications 80, seems to be confirmed by their wide-
spread use in depressive disorders associated with medi-
cal conditions 81-83 and in the elderly 84.
While assessing the role of adjunctive dopaminergic 
compounds in bipolar depression, another meaningful is-
sue to consider is their potential for cognitive benefit, as 
neurocognitive impairment is one of the most characteris-
tic feature of depressive phases 85. The only RCT targeting 
cognition with pramipexole conducted to date 49 reported 
mixed results, with the low affinity of pramipexole for 
D1 receptors, traditionally involved in working memory 
circuits 86, perhaps accounting for the lack of advantage 
in cognitive performance 63. Stimulant drug treatment fre-
quently leads to a significant improvement in memory, 
attention and executive functions, both in selected sub-
groups of patients with schizophrenia, ADHD 87 and in 
healthy subjects  88. However, further investigations in 
large clinical populations of patients with affective dis-
orders are needed to extend this data to mood disorder 
populations.
In terms of psychiatric safety/tolerability, it should be fur-
ther clarified whether the above-mentioned risks (mood 
switching, cycle acceleration, psychosis and abuse) 
should preclude their use in patients with a history of 
mood switching, rapid cycling or psychosis.
Taken together, the findings from the studies reviewed 
seem to suggest that pro-dopaminergic compounds ag-
onists, such as pramipexole and stimulant-like agents, 
deserve consideration as potential adjunct therapeutic 
agents in adult bipolar depression, at least in specific 
subgroups of patients, although caution for is still rec-
ommended. Future research and clinical trials on larger 
samples and greater follow-up periods are encouraged to 
extend the available evidence and better clarify the po-
tential role of these medications in bipolar depression.
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